Tamtam Try Tamtam free
Accendra Health logo

Accendra Health account plan

home-based care medical products

At a glance

Accendra Health (formerly Owens & Minor) is a US home-based care company, behind the Apria and Byram brands, with FY2025 net revenue of $2,762 million.

Accendra Health, Inc. (NYSE: ACH), the former Owens & Minor, became a pure home-based care company after selling its Products & Healthcare Services business on December 31, 2025. Through its Apria and Byram Healthcare brands it rents and sells home medical equipment and supplies across the United States: diabetes supplies, sleep therapy, home respiratory therapy, ostomy, wound care and urology. FY2025 net revenue from continuing operations was $2,762 million, up 3.1%, with adjusted EBITDA (non-GAAP) of $374.8 million and a GAAP loss from continuing operations of $102.7 million. Headquartered in Richmond, Virginia, it had over 6,500 teammates and more than 250 locations at the end of 2025.

Business units

Strategic priorities

Win referrals
Improve go-to-market and intake in respiratory and sleep, including faster adoption of e-prescribe digital referral management, which sits below industry peers; commercial operations now report to Chief Commercial Officer Scott Lloyd.
Keep patients on therapy
Supporting patients after setup becomes a North Star KPI, as material portions of new sleep patients lapse before the 90-day compliance window.
Revenue cycle management
Clean orders, on-time filing, fewer denials and faster rework, after weak collections hit revenue and adjusted EBITDA by nearly $20 million in the first half of 2026.
Rebuild branches and back office
Simplify and automate processes to cut cost to serve, with a first revamped version launching in Q1 and a transformation office running quarterly hard-dollar targets.
Deleveraging
Management targets long-range leverage of 3x adjusted EBITDA; net debt was $1.73 billion after Q3 2026, with no refinancing due until early 2029.

Latest results

In Q3 2026 net revenue fell 13.7% to $601.8 million (Q3 2025: $697.3 million), mainly because terminated commercial Payor contracts cost $82 million in the quarter; excluding that and a non-core asset sale, revenue was down 1%. Adjusted EBITDA (non-GAAP) was $47.8 million against $92.2 million, and the GAAP loss from continuing operations was $18.0 million. Cost of net revenue rose to 56.6% of revenue on lower collection rates. Full-year net revenue is now expected at the bottom end of the $2.45 billion to $2.55 billion range, and adjusted EBITDA could be as much as 30% lower than the $310 million midpoint of the prior outlook range.

Investments and deals

Sale of Products & Healthcare Services
Sold on December 31, 2025 for $375 million in cash, subject to adjustments, keeping a 5% equity interest; the business had $7,910 million of 2025 net revenue.
Balance Sheet Optimization Transaction
In June 2026 the 2029 and 2030 notes were exchanged for 9.000% first-lien notes due 2032 ($539 million) and 9.750% second-lien notes due 2033 ($698 million); Term Loan A was repaid.
Patient service equipment
Continuing-operations capex was $201 million in 2025, mostly patient service equipment; the CFO expects capex to be quite a bit lower in 2027 than 2026.
Terminated Rotech acquisition
The planned Rotech deal was terminated in June 2025, with an $80 million breakage fee paid to Rotech.

Challenges and risks

Payor concentration
The two largest commercial Payors were about 23% and 14% of 2025 net revenue; one terminated contracts worth $322 million, or 12% of 2025 net revenue.
Share loss and patient attrition
The CEO says the company has lost share in sleep and respiratory while the markets grew, citing high friction, slow order intake and inconsistent sales execution.
Liquidity and listing
Cash fell to $26.6 million at September 30, 2026, the total deficit was $568.2 million, and the NYSE sent notices on the share price below $1.00 and on market capitalisation and equity below $50 million.
Regulation and reimbursement
The June 2025 CMS coverage determination tightens home NIPPV qualification for COPD patients, alongside DMEPOS competitive bidding and Apria's Corporate Integrity Agreement.
Supplier dependence
The three largest suppliers made up about 40% of purchases in 2025.

What leadership says

“In sleep and respiratory, 2 of our most attractive businesses, we have lost share while the markets grew.”

Kenneth Gardner-Smith, President & CEO · Q3 2026 earnings call, November 5, 2026

“Our goal is to shift branches towards patient service and clinical hubs, not administrative warehouses.”

Kenneth Gardner-Smith, President & CEO · Q3 2026 earnings call, November 5, 2026

“The quarter was extremely disappointing as most of the near-term profit improvement efforts over the last few months did not yield the expected results.”

Jonathan Leon, EVP & CFO · Q3 2026 earnings call, November 5, 2026

“We're entering 2026 as a much leaner and more nimble business with a much higher margin profile”

Edward A. Pesicka, then President & CEO · Q4 2025 earnings call, February 19, 2026

Where a supplier can help

Digital referral and intake
Tied to the win-referrals priority: e-prescribe and order-intake software can raise digital referral adoption that sits below industry peers and reduce order rework.
Revenue cycle and denials management
Tied to the revenue cycle priority: claims, documentation and denials tools address collection rates that cost nearly $20 million in the first half of 2026.
Patient adherence engagement
Tied to the keep-patients-on-therapy priority: outreach and remote-monitoring tools can help new sleep patients reach the 90-day compliance window and return for resupply.
Back-office automation and logistics
Tied to the branch and back-office rebuild: automation and fulfilment partners fit a plan to cut cost to serve; the company already moved some fulfilment to logistics providers.
Cash-conscious commercial terms
Tied to the liquidity challenge: suppliers offering pay-for-performance or savings-backed pricing match a company with $26.6 million of cash and hard-dollar targets.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Accendra Health?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Accendra Health

What does Accendra Health do?

Accendra Health rents and sells home medical equipment and supplies in the US through its Apria and Byram Healthcare brands, covering diabetes, sleep therapy, home respiratory therapy, ostomy, wound care and urology.

What is Accendra Health's revenue?

FY2025 net revenue from continuing operations was $2,762 million. Q3 2026 net revenue was $601.8 million, and full-year 2026 revenue is expected at the bottom end of $2.45 billion to $2.55 billion.

How many employees does Accendra Health have?

Over 6,500 teammates at the end of 2025, across more than 250 locations.

Who leads Accendra Health?

Kenneth Gardner-Smith succeeded Edward A. Pesicka as President and CEO on October 5, 2026. Jonathan A. Leon is EVP and CFO and Scott Lloyd is Chief Commercial Officer.

Is Accendra Health the same as Owens & Minor?

Accendra Health is the former Owens & Minor, Inc., renamed after it sold its Products & Healthcare Services business on December 31, 2025.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)